New vaccine aims to train immune system against lymphoma
NCT ID NCT04669171
First seen Feb 01, 2026 · Last updated Jun 17, 2026 · Updated 20 times
Summary
This study tests a new vaccine (EO2463) designed to help the immune system fight indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. About 80 adults with follicular or marginal zone lymphoma will receive the vaccine alone or combined with standard drugs lenalidomide and rituximab. The goal is to find the safest and most effective dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU d'Amiens-Picardie - Hopital SUD
RECRUITINGAmiens, France
Contact
-
Clinica Universidad de Navarra
RECRUITINGMadrid, Spain
Contact
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Spain
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Hospital Clinico Universitario de Salamanca
RECRUITINGSalamanca, Spain
Contact
-
IRCCS Policlinico San Matteo Foundation - University of Pavia
RECRUITINGNaples, Italy
Contact
-
IRCCS Policlinico San Matteo Foundation - University of Pavia
RECRUITINGPavia, Italy
Contact
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
-
University Hospital Vall d'Hebron, Institute of Oncology
RECRUITINGBarcelona, Spain
Contact
-
University of Bologna
WITHDRAWNBologna, Italy
-
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
RECRUITINGRochester, New York, 14642, United States
Contact
-
University of Washington-Seattle Cancer Care Alliance
RECRUITINGSeattle, Washington, 98109, United States
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.